Compare GSK plc (GSK) vs Msci Inc (MSCI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Msci Inc — how do they compare? GSK plc trades at $46.54 (market cap $91.88B), while Msci Inc trades at $565.48 (market cap $40.38B). The key difference: GSK plc is far larger — about 2.3× Msci Inc's market cap, and GSK plc pays the higher dividend (3.9%). Which is the better fit depends on your goals — on Pluang, investors hold GSK plc for 93 Days and Msci Inc for 82 Days on average.
| GSK | MSCI | |
|---|---|---|
Market Cap | $91.88B | $40.38B |
Volume | 7,730,529 | 414,140 |
Sector | Health | Financials |
52-Week High | $61.18 | $643.83 |
52-Week Low | $43.24 | $511.84 |
Typical Hold Time | 93 Days | 82 Days |
Enterprise Value | $111.88B | $46.54B |
Dividend Yield | 3.9% | 1.48% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $46.50, down 1.11% with bearish technical signals, though RSI levels suggest potential oversold conditions. Fundamentally, the company shows strong profitability with 72.73% gross margins and consistent earnings beats, while maintaining a reasonable P/E of 14.89. Recent developments include strategic oncology partnerships and a $750M cancer therapy acquisition, positioning for long-term growth despite facing an HIV patent cliff.
GSK presents a mixed investment case with strong fundamentals and pipeline growth offset by technical weakness and patent expiration risks. The company's £40B sales target and cost-saving initiatives provide upside potential, while analyst consensus leans cautious with 55% hold ratings. Key risks include execution of pipeline development and competitive pressures in core markets.
MSCI trades at $565.12, up 1.75% today, with a bullish technical signal and strong analyst consensus. The stock shows robust fundamentals with 2025 revenue of $3.13B, net income of $1.20B, and high margins. Recent earnings beat expectations in Q4 2025 and Q1 2026, though Q2 2026 slightly missed. The company maintains strong cash flow and completed the acquisition of First Street in August 2026, enhancing its climate risk analytics offerings.
Outlook remains positive with a consensus price target of $701.71, implying significant upside. Key opportunities include recurring revenue growth and expansion in private markets. Risks include high valuation multiples, debt levels, and market sensitivity to financial services demand. Investors should weigh strong profitability against premium pricing and macroeconomic headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Msci Inc
MSCI describes its mission as enabling investors to build better portfolios for a better world. MSCI's largest and most profitable segment is its index segment, where it provides benchmarking to asset managers and asset owners. In addition, it boasts over $1 trillion in ETF assets linked to MSCI indexes. The MSCI analytics segment provides portfolio management and risk management analytics software to asset managers and asset owners. MSCI's all other segment was broken out into ESG and climate and private assets segments in 2021. In ESG and climate, MSCI provides ESG data to the investment industry. In the private assets side, MSCI provides real restate reporting, market data, benchmarking, and analytics to investors and real estate managers.
Read more on MSCI →
